Detalhe da pesquisa
1.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet
; 395(10218): 132-141, 2020 01 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31836199
2.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med
; 378(6): 518-528, 2018 02 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29231133
3.
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
N Engl J Med
; 366(19): 1759-69, 2012 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-22571200
4.
Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).
J Blood Med
; 12: 483-495, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34188580
5.
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.
Res Pract Thromb Haemost
; 5(6): e12576, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-34430790
6.
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Clin Lymphoma Myeloma Leuk
; 21(11): 785-798, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34344638
7.
Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).
J Blood Med
; 11: 213-225, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32607039